This clinical study is focused on myelodysplastic syndromes (MDS), a group of disorders caused by poorly formed or dysfunctional blood cells. The study is particularly for individuals who have low or intermediate-1 risk according to something called the IPSS scale, and who are dependent on blood transfusions. Moreover, these individuals have not responded well to a treatment known as ESA, which is supposed to stimulate red blood cell production. The therapy being tested here is called imetelstat (also known by the code GRN163L), administered as a solution directly into a vein. There is also a placebo being used for comparison in some parts of the study.

The main goal of this study is to evaluate if imetelstat is effective and safe for individuals with the specified type of MDS. This happens in two parts: the first part examines the treatment’s overall impact, while the second part compares its effects directly against a placebo. Additionally, there is an extension phase to assess long-term safety, survival rates, and disease progression, including potential progression to a more severe condition called acute myeloid leukemia (AML).

The study doesn’t just look at immediate effects; it also aims to observe longer-term outcomes like how long patients go without needing blood transfusions, any changes in their health status over time, and how they respond to the treatment regarding side effects. The study plan involves close monitoring of vital signs and lab results to ensure patient safety. Data collected will help understand the potential benefits of imetelstat for people with this form of MDS, whose current treatment options are limited.